Skip to main content

Table 2 Respondents views on trial design

From: The attitude of patients with progressive ataxias towards clinical trials

  FRDA all (%) FRDA trial naive (n = 59) (%) FRDA one trial (n = 49) (%) FRDA multiple trials (n = 61) (%) Inherited CA (%) Idiopathic CA (%)
Respondents who are trial experienced 63.9     12.7 4.5
Respondents very or extremely interested in participating in a future clinical trial 73.9 70.1 67.3 86.7 65.2 59.2
Respondents very or extremely interested in participating in a future clinical trial (drug repurposing) 75.2 74.1 73.4 81.9 53.1 50.9
Respondents willing to participate in phase of trial       
 Phase 1 57.4 50.8 48.9 60.6 68.3 65.3
 Phase 2 89.5 69.4 87.7 91.8 75.6 85.7
 Phase 3 77.1 69.4 55.9 77 78 40.8
Respondents very or extremely likely to participate in a future trial if they might be given a placebo 59.5 53.3 60.4 69.3 48.9 44.4
Respondents who would be very or extremely more willing to join a trial if an open label extension phase was offered 68.6 59.6 83.6 69.3 47.8 37.7
Respondents who felt it is either very or extremely important to have the results of a trial they participated in relayed back to them 84.5 87.1 87.5 83.3 81.3 78